RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER the larimar therapeutics, inc. 2020 equity INCENTIVE PLANRestricted Stock Unit Award Agreement • March 14th, 2023 • Larimar Therapeutics, Inc. • Pharmaceutical preparations
Pursuant to the Larimar Therapeutics, Inc. 2020 Equity Incentive Plan as amended through the date hereof (the “Plan”), Larimar Therapeutics, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of common stock, par value $0.001 per share (a “Share” or “Shares”) of the Company.
larimar therapeutics, inc. NON-QUALIFIED stock option grant notice and award agreement NON-PLAN INDUCEMENT AWARDAnd Award Agreement • March 14th, 2023 • Larimar Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Larimar Therapeutics, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) an non-qualified stock option to purchase the number of Shares set forth below (the “Option”). The Option is subject to the terms and conditions set forth in this Non-Qualified Stock Option Grant Notice (the “Grant Notice”) and the Award Agreement attached hereto as Exhibit A (the “Agreement”), which is incorporated herein by reference. This Option has been granted as an employment inducement grant pursuant to Rule 5635(c)(4) of the Marketplace Rules of NASDAQ Stock Market, Inc., is not issued under the Company’s 2020 Equity Incentive Plan, as amended through the date hereof (the “Plan”), and does not reduce the share reserve under the Plan. However, for purposes of interpreting the applicable provisions of this Option, the terms and conditions of the Plan (other than those applicable to the share reserve) shall govern and apply to this Option as if this Opti
SECOND AMENDMENT TO MASTER SERVICES AGREEMENTMaster Services Agreement • March 14th, 2023 • Larimar Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to the Master Services Agreement (“Second Amendment”) executed as of the date below with an effective date of September 20, 2022, (the “Second Amendment Effective Date”) by and among Larimar Therapeutics, Inc. (formerly Chondrial Therapeutics, Inc.), having an address at Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004 (“Client”) and KBI Biopharma, Inc. (“KBI Biopharma”) with an address at 1101 Hamlin Road, Durham, North Carolina 27704.
